Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone

Nadege Goumkwa Mafopa,1,3 Gianluca Russo,1,4 Raoul Emeric Guetiyawadoum,1,3,5 Emmanuel Iwerima,6 Vincent Batwala,6,7 Marta Giovanetti,3,5 Antonella Minutolo,5 Patrick Turay,3 Thomas B. Turay,8 Brima Kargbo,9 Massimo Amicosante,5 Maurizio Mattei,5 Carla Montesano2,3,5 Ebola Study Group
1University of Dschang, Dschang, Cameroon; 2University of Makeni, Makeni, Sierra Leone; 3Holy Spirit Hospital, Makeni, Sierra Leone; 4La Sapienza University of Rome, Rome, Italy; 5African Union Support to Ebola Outbreak in West Africa; 6Directorate of Research and Graduate Training, Mbarara University of Science and Technology, Uganda; 7Partner Relief Development, Freetown, Sierra Leone; 8Ministry of Health and Sanitation, Freetown, Sierra Leone

Abstract

A serosurvey of anti-Ebola Zaire virus nucleoprotein IgG prevalence was carried out among Ebola virus disease survivors and their Community Contacts in Bombali District, Sierra Leone. Our data suggest that the specie of Ebola virus (Zaire) responsible of the 2013-2016 epidemic in West Africa may cause mild or asymptomatic infection in a proportion of cases, possibly due to an efficient immune response.

Introduction

Ebola Virus Disease (EVD) spreads in communities through person-to-person transmission, with infection resulting from direct contact with blood, secretions, other body fluids or organs, and indirect contact with contaminated environmental materials or infected animals. In Sierra Leone, a total of 8704 confirmed cases and 3589 deaths were reported by the end of December 2015,1 of which 307 (221 deaths) were among health care workers (HCWs).2 In Bombali District, located in the northern region of the country, a total of 1050 confirmed EBV cases have been cumulatively reported since May 2013 to the end of December 2015. Retrospective serologic data3 suggest that EBOV might have been in circulation in Sierra Leone since 2006.

The role of antibody responses in viral clearance and protection against Ebola Virus (EBOV) in humans is not fully understood. Among EVD survivors, antibodies appear as early as day-5 after symptom onset, peak 2 weeks after recovery, then decline slowly over several years.4-7 In patients with fatal outcome, antibody titer rates are low or absent.8 The presence of detectable anti-EBOV antibodies in asymptomatic individuals suggests exposure and a putative role of antibody response in the control of EVD and provides information on EBOV seroprevalence in at risk populations.9 Monitoring anti-EBOV antibodies in EVD-community contacts (CCs) of index cases is crucial for assessing immune protection against EBOV. Due to the large number of infected HCWs, evaluation of anti-Ebola antibodies in this group is a useful tool for measuring the risk of occupational exposure to EBOV.

The aim of the study was to assess the extent of asymptomatic or mild cases of EBOV infection among the CCs of laboratory confirmed EVD cases (survivors or deceased) and in HCWs from health facilities not involved in the management of EVD cases.

Materials and Methods

Study populations

The study was conducted between February and March 2015 in the rural area of Sanda Loko Chiefdom, in the villages of Kamalo, Maron and Makasa (Figure 1) in the context of Ebola survivor Mobile Health Clinic program aimed to provide integrated primary healthcare services to address the medical and psychosocial needs of Ebola survivors living in areas with low medical coverage.10

A total of 6 EVD-deaths and 10 EVD-survivors were reported (Table 1). EVD cases were reported from Kamalo (4 deaths and 10 survivors) and Maron (2 deaths) villages, whereas no cases were reported from Makasa village (Table 2). EVD survivors were defined as individuals who showed EVD clinical signs or symptoms with EBOV infection confirmed by RT-PCR assay. Considering the organization of the local rural society, CCs were individuals from communities placed under quarantine.

In addition, seventy-nine HCWs were included in this study from Holy Spirit Hospital (n=59) and Loreto Clinic (n=20), two religious health care facilities in Makeni municipality (headquarter of Bombali District) that were not involved in the management of EVD cases (Table 1).

Correspondence: Carla Montesano, Tor Vergata University of Rome, via della Ricerca Scientifica 1, 00133 Rome, Italy. Tel.: +39.06.72594237 - Fax: +39.06.72494224. E-mail: montesano@uninroma2.it

Key words: Ebola virus infection; Sierra Leone; seroprevalence.

Acknowledgments: the data presented here were obtained with the financial support of the Italian Episcopal Conference (Camillian Task Force), the Italian Cooperation (Dokita ONG) and the Italian Geographical Society (Centro Relazioni con l’Africa). Authors wish to thank C.D. Pauza (Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA) for helpful discussions and language revision.

Contributions: NGM, GR and REGW contributed equally to this article as first authors. CM and MM contributed equally to this article as last authors. CM, GR had the original idea of the study; CM, GR, VB, MM designed the epidemiological survey; CM, GR, NGM wrote the manuscript; NGM, REGW, EI, MG, PT have participated in the fieldwork for collecting samples in the villages, treatment of samples and ELISA test; CM, MA, AM participated in the assessment of assay, in samples classification and performed statistical analysis; TBT, BK have organized the samples collection, supervising logistic.

We dedicate this work to the memory of Massimo Amicosante, colleague and friend, to honour his enthusiasm and his great scientific skill.

Received for publication: 30 June 2017. Accepted for publication: 1 July 2017.

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

©Copyright N.G. Mafopa et al., 2017

License: PAGPress. Italy Journal of Public Health in Africa 2017; 8:732 doi:10.4081/jphia.2017
tested questionnaires before obtaining 4 ml of peripheral blood by venipuncture.

**Anti Ebola virus antibody level**

Anti-Zaire Ebola Nucleoprotein (ZEBOV-NP) IgG antibodies were quantified using Enzyme-Linked Immunosorbent assay (ELISA) by a commercial kit (AE320620-1, Alpha Diagnostic International [ADI], Texas, USA), according to the manufacturer’s instructions. Positive control and calibrators provided by the kit were used in each test run. Optimal sample dilution was previously determined at 1:500 by testing 68 positive control plasma samples from EVD-survivors and 10 negative control plasma samples from expatriates not exposed to Ebola infection.

Threshold index to discriminate positive and negative antibody reactivity to ZEBOV NP was calculated following manufacturer’s instructions.

**Statistical analysis**

Data were collected and entered in a customized template in EpiData software version 3.1. The prevalence was calculated by dividing the number of seropositive cases by the number of examined individuals. Comparison among frequency of seropositive CCs from different villages was performed by one-tail Fisher’s exact test assuming the hypothesis of seroprevalence association.

**Results and Discussion**

Among Sanda Loko EVD survivors, all those enrolled from Kamalo were ZEBOV-NP-IgG positive (n=4/4). Anti-ZEBOV-NP-IgG were detected in 12 out of the 105 tested CCs (11.4% seroprevalence rate) (Table 1). As described in Table 2, the seroprevalence for ZEBOV-NP-IgG in CCs from different villages was 5.9% (n=3/51) in Kamalo, 20.0% (n=7/35) in Maron, and 10.5% (n=2/19) in Makasa.

Among HCWs (Table 1), no ZEBOV- seropositive cases were found in the Loreto Clinic group (n=0/20), whereas 3 seropositive cases (1 nurse and 2 cleaners) out of 59 (5.8%) were found at the Holy Spirit Hospital. Overall, the seroprevalence among HCWs was 3.8% (n=3/79).

ZEBOV-seropositive CCs did not report fever or other symptoms/signs suggestive of EVD during the previous 8 months. Three of them reported mild, non-specific symptoms, including headache (n=1), joint pain (n=1), or both (n=1). Risk behaviours, such as hunting activity in the forest, or participating in a burial service during the past 8 months, were reported by one and two persons respectively.

Although the knowledge of Ebola dynamics, pathogenesis and clinical course is improving, some aspects remain unclear, including the role for naturally-acquired humoral immunity.

The influence of humoral immunity on EVD outcome was observed in Gabon8 and confirmed by a serosurvey in Uganda.7 A larger EBOV serosurvey in Gabon7 showed significant seroprevalence across the country even in areas considered Ebola-free, and raised important questions about EBOV spread, virulence and the existence of natural protective immunization.

The overall seroprevalence rate among asymptomatic CCs in the area of Sanda Loko Chieftdom was 11.4% with significant differences observed among the three villages. Anti-EBOV-positive subjects were found in all villages with or without confirmed EVD cases. Interestingly, the highest seroprevalence rates was observed in villages with the lowest incidence of EVD cases (P<0.05, Table 2) suggesting that EBOV circulated in those populations without causing disease.

In this paper we report a high seroprevalence in asymptomatic CCs of Sanda Loko Chieftdom although we have recently shown that only 2.6% (10 of 388) of asymptomatic members of Ebola-affected households had evidence of Ebola virus infection in Sierra Leone.11 The extend of asymptomatic EBOV infection is still unclear and several studies reported a wide variability of seroprevalence (from 1% to 46%),9,12-14 among the household and CCs. This high variability can be ascribed to the different antigens and assays used and also the definition of contact varied in the studies.

The seroprevalence rate among all HCWs was 3.8% even if the health facilities where they worked were not included in the network for managing EVD cases. We cannot rule out that they may have been exposed to EVD outside the work place. The observed moderate grade of EBOV infection association.

**Table 1. Prevalence of ZEBOV-seropositivity in EVD survivors, community contacts and health care workers.**

| Village                  | Tested (n) | Seropositives (n) | Seroprevalence (%) |
|--------------------------|------------|-------------------|--------------------|
| Sanda Loko EVD-survivors | 10*        | 4                 | 4                  | 100                |
| Sanda Loko EVD deaths    | 6          | -                 | -                  | -                  |
| Sanda Loko CCs           | NA         | 105               | 12                 | 11.4               |
| Total HCWs               | 79         | 79                | 3                  | 3.8                |
| Holy Spirit Hospital     | 59         | 59                | 3                  | 5.8                |
| Loreto Clinic            | 20         | 20                | 0                  | 0                  |

*4 survivors were enrolled and tested in this study. NA, not available.

**Table 2. EVD deaths and survivors, community contacts and seroprevalence in Sanda Loko Chieftdom villages.**

| Village | Deaths (n) | Survivors (n) | CCs (n*) | Anti-ZEBOV positive CCs (n) | Seroprevalence (%) among CCs |
|---------|------------|---------------|----------|----------------------------|-----------------------------|
| Kamalo  | 4          | 10*           | 51       | 3                          | 5.9*                        |
| Maron   | 2          | 0             | 35       | 7                          | 20.0                        |
| Makasa  | 0          | 0             | 19       | 2                          | 10.5                        |

*CC (n) refers to the number of Community Contacts included in this study; *four survivors were enrolled and tested in this study; P<0.05.
transmission in HCWs needs further analysis of larger groups, along with assessing the adherence to use of personal protection (gowns, gloves, masks). This data is consistent with previous serosurvey performed in Gabon and led to hypothesis that the host-EBOV interaction might determine the development of specific antibodies capable to control the infection, leading to mild or asymptomatic EVD.

Our findings that anti-ZEBOV-IgG was detected in both EVD-survivors and CCs, although at different prevalence rates, suggests that the immunity, previously reported as persistent among survivors, may be important for protection that allowed subclinical disease among CCs.

Conclusions

Our study provides significant new insight into population exposure to EBOV and outcomes of virus infection. This causes us to question the assumption that EBOV is highly fatal. Instead, EBOV, similar to Lassa Fever virus and many other viral pathogens, may have high fatality as a proportion of clinical cases but relatively high seroprevalence among persons without evidence of clinical disease among persons without evidence of clinical disease arguing that the fatality rate is actually lower than has been predicted. These findings raise important questions about EBOV pathogenicity and argue that some individuals have achieved long lasting protection following attenuated infection that should be taken in account for vaccine programs.

There is a strong rationale for expanding the serological screening of exposed populations and HCWs in countries affected by EVD to understand their risk of infection and to guide the implementation of quarantine when needed, and vaccine programs when available.

Ebola Study Group

Joseph Turay (University of Makeni, Makeni, Sierra Leone); Mahmoud B. Kargbo (Partner Relief Development, Freetown, Sierra Leone), Martin Sanou Sobze (University of Dschang, Dschang, Cameroon), Marina Potestà (University of Rome "Tor Vergata", Rome, Italy), Massimo Ciccozzi (National Institute of Health – ISS, Rome, Italy), Giovanni Rezza (National Institute of Health – ISS, Rome, Italy), Jeffrey R. Dorfman (International Center for Genetic Engineering and Biotechnology, Cape Town, South Africa; University of Cape Town, Cape Town, South Africa).

References

1. Ministry of Health and Sanitation, Sierra Leone. Ebola virus disease - Situation report; 24 December 2015. Available from: http://nerc.sl/sites/default/files/Ebola%20Situation%20Report%20Vol%20575.pdf
2. World Health Organization (WHO). Ebola Situation Report; 30 December 2015. Available from: http://apps.who.int/ebola/current-situation/ebola-situation-report-30-december-2015
3. Schoepf RJ, Rossi CA, Khan SH, et al. Undiagnosed acute viral febrile illness: a cross-sectional study. Emerg Infect Dis 2014;20:1176-82.
4. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 1999;179:S28-35.
5. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179:S177-87.
6. Wauquier N, Becquart P, Gasquet C, Leroy EM. Immunoglobulin G in Ebola outbreak survivors, Gabon [Letter]. Emerg Infect Dis 2000.
7. Sobarzo A, Groseth A, Dolnik O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 2013;208:299-309.
8. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola-virus-infected patients. Nat Med 1999;5:423-26.
9. Becquart P, Wauquier N, Mahlakõiv T, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010;5:e9126.
10. Guettiya Wadoum RE, Samin A., Goumkwa Mafopa N, et al. Mobile Health Clinic for Medical Management of Clinical Sequelae Experienced by Survivors of the 2013-2016 Ebola Virus Disease Outbreak in Sierra Leone, West Africa. Eur J Clin Microbiol Infect Dis 2017; 36:2193-200.
11. Glynn JR, Bower H, Johnson S, et al. Asymptomatic infection and unrecognized Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infect Dis 2017;17:645-53.
12. Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015;15:905-12.
13. Richardson ET, Kelly JD, Barrie MB, et al. Minimally symptomatic infection in an Ebola 'hotspot': a cross-sectional serosurvey. PLoS Negl Trop Dis 2016; 10:e0005087.
14. Leroy EM, Baize S, Volechkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355:2210-15.
15. Fhogetaig CN, Aarons E. Viral haemorrhagic fever. Clin Med 2015;15:61-6.
16. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2007. pp 1409-1448.